About
Who We Are
Microbion is a clinical-stage pharmaceutical company pioneering a novel class of compounds to address resistant and hard-to-treat infections, as well as chronic and rare conditions driven by excessive inflammation. Our lead therapeutic candidate, pravibismane, has shown potent, broad-spectrum antimicrobial activity against a wide array of pathogens—including multiple “superbugs” identified by the US Centers for Disease Control and Prevention (CDC). This includes potent efficacy against carbapenem-resistant Enterobacteriaceae (CRE), all ESKAPE pathogens, and antibiotic-resistant fungal strains.
Pravibismane also uniquely prevents and eradicates microbial biofilms, a major challenge in treating persistent infections. This dual antimicrobial and anti-biofilm action positions pravibismane as a potential first-in-class, best-in-class solution for serious and life-threatening infections.
Beyond its antimicrobial properties, pravibismane demonstrates direct anti-inflammatory and immunomodulatory effects, helping to resolve chronic, dysfunctional inflammation and promote tissue healing—key factors in many chronic conditions.
At Microbion, we are committed to transforming the treatment landscape for infections and inflammatory diseases through innovative science and a patient-focused approach.